Biotech Values

[genisi]

the FDA reviewers think Eliquis has something to offer in this indication beyond what Pradaxa and Xarelto can. The data for Eliquis in warfarin-intolerant patients provides such a justification

Also, Eliquis is the only one that showed stat-sig reduction in all cause mortality compared to warfarin (in ARISTOTLE trial). Pradaxa and Xarelto were both approved with non inferiority and given Eliquis data it should get superiority clam vs warfarin in its AFib label.